YiLinCloud Secures Tens of Millions in New Funding Amid Capital Winter to Accelerate AI-Driven Transformation in Clinical Research

Recently, ECLINCLOUD (Ningbo) Technology Co., Ltd. (hereinafter referred to as “ECLINCLOUD”) announced the completion of a new round of financing amounting to tens of millions of yuan, exclusively led by the renowned biomedical investment firm Hongfeng Investment. Against the backdrop of a global capital winter, this financing not only underscores ECLINCLOUD’s robust capabilities in AI-driven clinical research but also marks a solid step forward in its journey to promote intelligent transformation within the industry. The funds will further accelerate ECLINCLOUD’s in-depth R&D and innovative applications of AI technologies, while supporting the company’s expansion of its global strategic layout, thereby injecting stronger digital momentum into new drug development and clinical research for medical devices.

ECLINCLOUD is an industry-leading AI technology company dedicated to reshaping the industrial landscape through cutting-edge technologies. The company’s team comprises medical experts from top-tier international enterprises such as Pfizer, Novo Nordisk, and IQVIA, as well as technical elites from tech giants like IBM and Oracle. Its core team boasts over 15 years of experience in new drug development at internationally leading technology companies or innovative pharmaceutical firms. Furthermore, ECLINCLOUD’s independently established AI Innovation Center brings together artificial intelligence experts and advisory teams from the industry, providing robust support for technological breakthroughs.

Leveraging its robust AI capabilities, ECLINCLOUD has pioneered the deep integration of technology across the entire clinical research value chain—from trial design and data collection to analysis, patient management, and process optimization—significantly enhancing efficiency while reducing costs.Currently, the company has established in-depth collaborations with leading domestic pharmaceutical and CRO companies, accumulating over 1,000 successful cases, including multiple large-scale international Phase III clinical trials. This has helped clients significantly shorten their R&D cycles and solidified the company’s leading position in the industry.

Since its inception, ECLINCLOUD has consistently developed its products and services in accordance with international standards. Its independently developed SaaS cloud platform supports multi-language operations and is deployed on cloud infrastructure in both China and the United States. Users can flexibly select data storage locations based on project requirements, ensuring data security and compliance while fully meeting regulatory requirements in regions such as the United States and the European Union. This technical architecture has successfully supported numerous multinational, multi-center research projects, fully demonstrating its global competitiveness.

Going forward, ECLINCLOUD will continue to expand its international talent pool and deepen its global collaboration network, empowering clients to efficiently implement their internationalization strategies and further solidifying its core position in the field of digital clinical research worldwide.

Dr. Qin Long, Founder & CEO of ECLINCLOUD, stated“Securing financing amid the capital winter is a dual affirmation of ECLINCLOUD’s technological strength and industry value. Clinical research is entering a new phase characterized by intelligent efficiency enhancement. We will continue to focus on AI-driven solutions, deeply addressing industry pain points across the entire value chain of new drug development, and helping global customers accelerate the market launch of innovative drugs.”

ECLINCLOUD is a leading AI technology company in the clinical research industry. By leveraging AI to build an integrated intelligent cloud platform for clinical trials and endpoint assessment technologies, it provides global pharmaceutical companies and research institutions with technical products such as eCOA, CTMS, eTMF, EDC, RTSM, IRC, and RM, as well as services including scale management, linguistic validation, rater training, and data quality analysis. It constructs efficient and precise digital solutions, and relies on AI prediction models and intelligent data platforms to dynamically assess and help improve the success rate of drug clinical trials, thereby accelerating the R&D cycle of drugs and medical devices and benefiting patients.

Ningbo Hongfeng Investment Management Co., Ltd. (hereinafter referred to as “Hongfeng Investment”), a renowned venture capital and private equity fund management firm in the biopharmaceutical industry, relies on the Ningbo Hangzhou Bay Life Science Park. It focuses on investing in start-up and growth-stage biopharmaceutical enterprises, with deep expertise in new drug R&D, cell and gene therapy, ophthalmology, medical devices, and other fields.